Epigenomics AG Successfully Places Shares at Premium in Capital Increase

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

companies/Diagnostics

Berlin (euro adhoc) - 12. February 2009 - Epigenomics AG (Frankfurt,
Prime Standard: ECX; ISIN: DE000A0BVT96) successfully placed all
2,671,088 new shares that were issued in an increase of the share
capital against contribution in cash and without subscription rights
that was decided upon yesterday by its Executive and Supervisory
Boards. A 100% subsidiary of BB MEDTECH AG (Schaffhausen,
Switzerland) and funds managed by Abingworth LLP (London, UK)
subscribed for all the new shares.

The issue price was set at EUR 1.94 per share. This constituted a 5%
premium over and above the volume-weighted average XETRA trading
prices over the five trading days preceding the announcement of the
capital increase. The capital raise at this premium leads to gross
proceeds of approximately EUR 5.18 million. After registration of the
capital increase the signed capital of Epigenomics AG will increase
from its current EUR 26,723,636 to a total of EUR 29,394,724
thereafter.

ICF Kursmakler AG (Frankfurt, Germany) will coordinate the
registration of the new shares with the Frankfurt Stock Exchange.
Trout Capital LLC (New York, NY, USA) acted as sole financial advisor
to Epigenomics in this transaction.

Epigenomics intends to apply the proceeds from this transaction
towards the final stages of product development and commercialization
of its most advanced product, a blood-based molecular diagnostic test
for the early detection of colorectal cancer. Proceeds will also be
used for clinical research and product development in Epigenomics'
lung cancer and prostate cancer programs.

"We are very pleased that in BB MEDTECH and Abingworth LLP we have
major shareholders that share our vision and strategic direction to
develop Epigenomics into a leading cancer molecular diagnostics
company over the next several years" commented Geert Nygaard, Chief
Executive Officer of Epigenomics on the transaction. "These investors
have unique expertise in the diagnostics and medical device industry
and a team of very experienced specialists in this sector. This will
help medium and long-term to provide Epigenomics with the financial
stability that we need for the successful commercialisation of our
products."

"We believe in a continued dynamic development of the molecular
diagnostics market segment in the years to come. After the
development of technological platforms in the past several years,
content based on these technologies like cancer tests will be in the
focus in the future. Epigenomics may be one of those specialized
companies who get to market early", said Laura Rossi, head of the BB
MEDTECH management team.

"We are particularly pleased to have raised the capital at a share
price significantly above the most recent rights issue price of
February 2008 despite the extremely challenging capital markets
environment and global financial crisis. This is testament to the
solid fundamentals and excellent progress we have made in executing
our business plan", Geert Nygaard added.

After settlement, the BB MEDTECH group will have doubled its stake in
Epigenomics to about 14.9% from about 7.4% before the transaction and
will be Epigenomics' second largest shareholder after Federated
Investors Inc. (Pittsburgh, PA, U.S.A.). Funds managed by Abingworth
LLP will own about 11.1%.

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests in development aim at diagnosing
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.

Epigenomics' product pipeline contains a validated biomarker for the
early detection of colorectal cancer in blood plasma, and further
proprietary DNA methylation biomarkers at various stages of
development for prostate and lung cancer detection in urine, blood
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample
demonstrated continuously highest performance in multiple clinical
studies with in total about 3,500 individuals tested.

For development and global commercialization of in vitro diagnostic
test products, Epigenomics pursues a non-exclusive partnering
strategy. Strategic diagnostics industry partners include Abbott
Molecular, Philips, Sysmex Corporation and Quest Diagnostics for
diagnostics test products, and QIAGEN N.V. for sample preparation
solutions and research products.

Partners in the health care industry and the biomedical research
community can access Epigenomics' portfolio of proprietary DNA
methylation technologies and biomarkers protected by more than 150
patent families through research products, Biomarker Services, IVD
Development Collaborations, and Licensing. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary
in Seattle, WA, U.S.A. For more information, please visit
Epigenomics' website at www.epigenomics.com.

Epigenomics' legal disclaimer. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

Disclaimer relating to US Securities Laws. The sale of the common
stock will not be registered under the Securities Act of 1933, as
amended (the "Securities Act"), or applicable state securities laws.
The shares will be sold pursuant to applicable exemptions from the
registration requirements of the Securities Act. Unless registered,
the shares may not be offered or sold in the United States except
pursuant to an exemption from the registration requirements of the
Securities Act and applicable state securities laws. This news
release does not constitute an offer to sell or the solicitation of
an offer to buy the securities.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum

Sen. VP Corporate Development

Epigenomics AG

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade